New in­vestors pool $120M to bankroll Al­lo­gene's off-the-shelf CAR-T pipeline in dri­ve to stay in the lead

It was clear from Al­lo­gene Ther­a­peu­tics’ day 1 that Arie Bellde­grun and David Chang were in no short­age of in­vestors ea­ger to back their al­lo­gene­ic CAR-T ther­a­pies: They gath­ered $300 mil­lion in short or­der from a syn­di­cate that fea­tures Pfiz­er, TPG and Vi­da Ven­tures.

The pair of Kite vets have dri­ven the point home again with a $120 mil­lion pri­vate fi­nanc­ing an­nounced Thurs­day morn­ing as they worked to fill out the full team of ex­ecs who will run the show.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.


Alexandria Real Estate Equities

San Diego, CA, USA